Vascular BioSciences to Make Six Presentations at the American Thoracic Society in San Francisco from May 15 – May 18
Vascular BioSciences to present the full scope of its research efforts at this year’s ATS International Conference
Goleta, CA, May 12, 2016 – Vascular BioSciences announces that it will be making six presentations at the American Thoracic Society 2016 International Conference, taking place on May 13-18, 2016 in San Francisco, CA.
On Sunday, May 15, Vascular BioSciences will be presenting Abstract A2230 – Oral CAR Peptide Adjuvant Enhances Sildenafil Therapy for Pulmonary Arterial Hypertension, (please see: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A2230) as well as Abstract A2231 – CAR Peptide Adjuvant Enables Effective Pulmonary Hypertension Treatment with Imatinib at Reduced Doses, (please see: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A2231). This research, performed in collaboration with Dr. Masanobu Komatsu and colleagues at the Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Florida, will be presented from 11:00 a.m. to 12:45 p.m. in A66-PH: Molecules, Cells, and Animal Models session in Area M, Hall D (North Building, Lower Level) of the Moscone Center in San Francisco, CA.
Also on Sunday, May 15, Vascular BioSciences will be presenting Abstract A2733 – Highly Effective Treatment of Endothelial Disorders in Sepsis by CAR Peptide Adjuvant for Hydrocortisone (please see: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A2733 ). This research, performed in collaboration with Dr. Hideshi Okada and colleagues at the Gifu University Graduate School of Medicine in Gifu, Japan, and Dr. Masanobu Komatsu, will be presented from 2:15 p.m. to 4:15 p.m. in session A104 – Critical Care: Sepsis Translational Insights in Room 3001, West Building, Level 3 of the Moscone Center.
On Monday, May 16, 2016, Vascular BioSciences will present Abstract A3902 – MicroRNA and Gene Dysregulation in Pulmonary Hypertension: Experimental Findings in a Large Animal Model Compared to Predictions by a Systems Biology Approach (please see http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A3902). as well as Abstract A3903 – CARSKNKDC (CAR) Selective Enhancement of Fasudil-Induced Pulmonary Vasodilation in a Porcine Model of Chronic Pulmonary Hypertension (please see: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A3903). This research, performed in collaboration with Dr. Abraham Rothman and colleagues at the Children’s Heart Center Nevada and the University of Nevada, School of Medicine, Las Vegas, will be presented from 11:00 a.m. to 12:45 p.m. in B53-PHound in Translation session in Area A, Hall D (North Building, Lower Level) of the Moscone Center.
On Wednesday, May 18, 2016, Vascular BioSciences will be presenting Abstract A7300 – Differential Response to Serial Microsphere Infusions During Creation of Canine and Porcine Models of Pulmonary Hypertension (please see: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A7300 ). This research, performed in collaboration with Dr. Abraham Rothman, will be presented from 11:00 am to 12:45 p.m. in D52-Molecular Insight Into Pulmonary Hypertension session in Area H, Hall D (North Building, Lower Level) in the Moscone Center.
Vascular BioSciences CEO and co-author David Mann commented, “This conference represents a unique opportunity to communicate with members of the international medical community the full breadth of Vascular BioSciences’ research efforts.”
About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.
For more information about VBS is available at www.vascularbiosciences.com
For more information, please contact email@example.com
About ATS 2016 and The American Thoracic Society
ATS 2016 International Conference, which is one of the largest gatherings of pulmonary, critical care and sleep medicine clinicians and researchers in the world.
The American Thoracic Society improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.